Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GRAIL Inc (GRAL)
NASDAQ:GRAL
Holding GRAL?
Track your performance easily
GRAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.33 - $29.79
Previous CloseN/A
Volume371.20K
Average Volume (3M)1.08M
Market Cap
$961.32M
Enterprise Value-$324.48M
Total Cash (Recent Filing)$241.60M
Total Debt (Recent Filing)$82.67M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Aug 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-67.93
Shares Outstanding33,600,773
10 Day Avg. Volume1,255,060
30 Day Avg. Volume1,082,377
Standard Deviation0.13
R-Squared0.37
Alpha-0.00433
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.22
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.34
Enterprise Value/Revenue-5.86
Enterprise Value/Gross Profit3.39
Enterprise Value/Ebitda1.02
Forecast
1Y Price Target
$16.00Price Target Upside-39.98% Downside
Rating ConsensusHold
Number of Analyst Covering2
GRAIL Inc News
Bulls Say, Bears Say
Bulls Say
Innovative ProductGRAL’s Galleri multi-cancer early detection screening test has the potential to address a significant unmet need.
Pioneering TechnologyGRAIL is the pioneer in MCED testing, an exciting and large opportunity, if it works.
Strategic Financial ManagementCash preservation efforts are encouraging with Medicare reimbursement as a key catalyst to unlocking value.
Bears Say
Financial StabilityAdditional financing will likely be required to build out commercial infrastructure for successful market penetration.
Operational RisksA massive RIF cuts costs but also commercial heft, with potential margin impacting ASP pressures and a multi-year timeline to a potential FDA and CMS regulatory and reimbursement pathway raising concern.
Regulatory ChallengesBroad reimbursement and adoption hinge on the NHS-Galleri readout and subsequent FDA approval, which are several years away.
---
Ownership Overview
28.55% Insiders
12.27% Mutual Funds
0.93% Other Institutional Investors
49.71% Public Companies and Individual Investors
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
GRAIL Inc lowest stock price was $12.33 and its highest was $29.79 in the past 12 months.
What is GRAIL Inc’s market cap?
GRAIL Inc’s market cap is $961.32M.
When is GRAIL Inc’s upcoming earnings report date?
GRAIL Inc’s upcoming earnings report date is Aug 19, 2025 which is in 200 days.
How were GRAIL Inc’s earnings last quarter?
GRAIL Inc released its earnings results on Nov 12, 2024. The company reported -$3.94 earnings per share for the quarter, beating the consensus estimate of -$6.43 by $2.49.
Is GRAIL Inc overvalued?
According to Wall Street analysts GRAIL Inc’s price is currently Overvalued.
Does GRAIL Inc pay dividends?
GRAIL Inc does not currently pay dividends.
What is GRAIL Inc’s EPS estimate?
GRAIL Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GRAIL Inc have?
GRAIL Inc has 33,600,773 shares outstanding.
What happened to GRAIL Inc’s price movement after its last earnings report?
GRAIL Inc reported an EPS of -$3.94 in its last earnings report, beating expectations of -$6.43. Following the earnings report the stock price went up 5.5%.
Which hedge fund is a major shareholder of GRAIL Inc?
Currently, no hedge funds are holding shares in GRAL
---
GRAIL Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$16.00 (-39.98% Downside)
$16.00 (-39.98% Downside)
Blogger Sentiment
Bullish
GRAL Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 435.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $426.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
GRAIL Inc
GRAIL is a healthcare company innovating to solve medicine's most important challenges. The Company's team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable.
---
GRAL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong revenue growth and improved financial performance, driven by increased demand for the Galleri test. However, ongoing net losses and future revenue growth constraints due to lack of broad reimbursement temper the positive outlook. The company's strategic focus on FDA approval and reimbursement is critical for future scalability.Read More>---
Technical Analysis
---